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Abstract 
Iloperidone is a new atypical antipsychotic drug approved by FDA for the treatment of schizophrenia. In 
this article, we searched the published randomized controlled trials (RCT) and other literature to review 
the efficacy and safety of iloperidone using the following database (Science Direct, PubMed) and 
illustrate its role in the management of schizophrenia. Iloperidone showed efficacy by causing 
significant improvements in psychiatric scales such as Positive and Negative Syndrome scale (PANSS) 
and clinical global impressions (CGI). Iloperidone was associated with a number of common side 
effects such as metabolic and cardiovascular side effects. This review illustrated that iloperidone was 
well tolerated with significant improvements in disease severity and symptom intensity control in patients 
suffering with schizophrenia, however, iloperidone was associated with a significantly higher risk of 
metabolic and cardiovascular side effects with minimal extrapyramidal side effects. These findings would 
guide psychiatrists and pharmacists in their clinical role for supporting the care of psychiatric patients. 
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Introduction 
Schizophrenia is a chronic and debilitating psychiatric disorder with significant morbidity and 
mortality (1) with a substantial impact on the patients and their carers’ psychological, physical 
and social life (2). Despite the available management options, several patients suffer from 
treatment-resistant or poor prognosis (3). Schizophrenia prevalence is 0.5%-1% worldwide (4) 
with the associated management challenges such as frequent antipsychotics switching and poor 
compliance (5). Atypical antipsychotics are the main group of pharmacological treatments used 
in the management of schizophrenia due to their favourable side effects (SE) profile compared to 
the typical antipsychotics (6).  
Iloperidone, a new second generation antipsychotics (SGA) with similar structure to risperidone 
(7), is used for the management of schizophrenia and other psychotic disorders (8). The 
recommended iloperidone daily dose is 12-24 mg divided as 2 doses (9) with recommended dose 
titration - starting dosage of 1 mg twice daily to minimize postural hypotension and target dose 
of 6 mg bid achieved in 4 – 7 days (10,11).    
Iloperidone: Pharmacodynamics and pharmacokinetics 
Iloperidone has strong affinity for noradrenaline, dopamine, and serotonin receptors. At clinical 
doses, iloperidone blocks 5-HT2A receptors and reduces dopamine D2 receptor-mediated 
neurotransmission (12). Iloperidone also binds to D3, alpha2C, 5-HT1A, and 5-HT6 receptors 
(13). 5-HT1A stimulation and 5-HT6 antagonism are of primary importance for iloperidone 
possible beneficial effects on cognition (12). Iloperidone strong 5-HT2A antagonism could 
stimulate histamine neuron activity with pro-cognitive properties (14). Research using computer 
models suggested that the clinical effects of iloperidone occur through dopamine receptor 
coupling in cortical neurons (15). 
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Iloperidone also affects the noradrenergic system (alpha2C antagonism) resulting in cognitive 
symptoms changes as iloperidone, when compared with other antipsychotics, has the highest 
alpha2C/alpha2A ratio (16). Iloperidone also increased dopamine and acetylcholine release in the 
medial prefrontal cortex via actions on 5-HT1A (17), increased dopa accumulation in response to 
D2 receptor antagonism with clozapine-like effects (18) and decreased 5-HT2 receptors (19). 
Administered orally, iloperidone is well absorbed with 96% bioavailability (20), highly bound to 
plasma proteins (21). Peak serum concentration is achieved within 2 - 3 hours and eliminated 
slowly (t1/2 14 hours) (22). Iloperidone was extensively metabolized with CYP1A2, CYP2E1, 
CYP2D6 and CYP3A4 enzymes (23). When prescribing iloperidone, CYP2D6 extensive and 
poor metabolizers need to be checked (24) due to different plasma concentrations of iloperidone 
and its metabolites (25); for example, elimination half-life was 18 h for extensive CYP2D6 
metabolizers and around 33 h for poor CYP2D6 metabolizers (26). Iloperidone major metabolite 
has receptor affinity profile similar to iloperidone and likely to contribute to its clinical effects 
(27). Iloperidone quality, safety and efficacy could also be affected by acidic, basic hydrolysis 
and oxidative degradation (8). 
Iloperidone efficacy in human studies 
Iloperidone showed efficacy in relapse prevention in schizophrenia (relapse rates was just 20% 
compared to around 63% for placebo) with longer mean time to relapse (139 days versus 
71 days) (28). In a big clinical trial with 500 patients on risperidone, olanzapine, or aripiprazole 
switched to iloperidone, improvement in Clinical Global Impression (CGI) scale was observed 
(29,30). Iloperidone was also associated with improved Brief Psychiatric Rating Scale (BPRS), 
Positive and Negative Syndrome Scale-total (PANSS-T) score, and PANSS-positive and 
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PANSS-negative scores (31). Further two trials confirmed iloperidone beneficial decrease of 
PANSS-T (11,32).  
Iloperidone ameliorated excitement/hostility; depression/anxiety; cognition; positive and 
negative scales (33) and was successful in improving mania and depression scores in mixed 
mood states, considered difficult to manage in bipolar disorders (34). As iloperidone has the 
highest affinity to alpha-1 compared to other antipsychotics, it could be helpful in posttraumatic 
stress disorder management like prazosin (alpha-1 antagonist) with its D2 and 5-HT2 antagonist 
activities reducing hypervigilance (35). 
Iloperidone efficacy in animal studies 
Cognitive functions are normally impaired in schizophrenia, while iloperidone showed efficacy 
in improving choice accuracy (36) and cognitive dysfunction in rat models (37). In experiments 
using apomorphine and phencyclidine, pre-treatment with iloperidone demonstrated beneficial 
behavioural actions (38). Iloperidone increased social interaction (39) with its weak D2 and 
potent alpha-2 antagonism helping to reduce alcohol drinking issues (40).  
Safety and tolerability of Iloperidone 
Iloperidone most common side effects (SE) were dizziness (5.1%-23.2%), somnolence (4%-
13%), dyspepsia (4.8%-7.8%), insomnia (18.1%), anxiety (10.8%) and dry mouth (5.2%-10.4%) 
with low rates of extrapyramidal disorder (2.5%) or akathisia (3.7 %) (11,28,41). A dose 
relationship for dizziness, somnolence and dry mouth existed; e.g. number to harm (NNH) for 
somnolence was 25 for iloperidone 10-16 mg/day and 10 for 20-24 mg/day (42). Nasal 
congestion, fatigue, sedation and tachycardia occurred especially with higher doses (31). Long-
term management with high doses caused SE such as headache (13.9%), weight increase (9.2%), 
dizziness (6.9%), nausea (6.4%), sedation (6.4%) and insomnia (5.2%) (43). Iloperidone was 
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also associated with a moderate risk of metabolic syndrome or cardiovascular events (44). 
Statistically significant changes in serum glucose found with ≥7% weight increase (NNH = 11) 
(45), with young or low baseline body mass index patients most vulnerable (44). Iloperidone 
prolongs QTc interval to a higher extent compared to quetiapine and co-administration of 
metabolic inhibitors could further increase risk of QTc changes especially in patients with 
CYP2D6 polymorphisms (46). Moreover, alpha 2c antagonism could lead to ventricular 
premature contractions (47) and predispose to cardiac arrhythmias and sudden death; no patient 
suffered from QT interval of 500 msec or greater (32). Iloperidone has a favourable prolactin 
profile compared to other antipsychotics, but is associated with disorders of ejaculation such as 
priapism due to its alpha1- antagonist properties (48-50).  
Withdrawal of iloperidone could lead to increased heart rate/palpitations and urinary 
incontinence (34), hence gradual withdrawal/switching is recommended (29). Discontinuation 
with iloperidone due to SE was just 4.8% compared to 7.6% for haloperidol and 6.2% for 
risperidone (51). Caution is needed in elderly patients due to orthostatic SE (9). Iloperidone 
could increase the incidence of psychotic disorders during the postpartum period (52) with 
limited safety data for iloperidone in breast feeding (53). Reported rare SE include respiratory 
depression (54); angioedema (55), neuroleptic malignant syndrome (56) and Tardive Dyskinesia 
(57). Combinations with other psychiatric medications result in pharmacokinetic and 
pharmacodynamic interactions such as increase in QTc interval when fluoxetine or paroxetine 
co-administered with iloperidone (58). Iloperidone co-administered with fluoxetine resulted in 
significant weight gain (59), while its use while patients taking illicit drugs (e.g. cocaine) led to 
respiratory failure with mandated respiratory support and prolonged QTc (60). 
Pharmacogenomics 
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Polymorphisms associated with iloperidone efficacy were identified within the neuronal PAS 
domain protein 3 gene (NPAS3) (61) with  more than 75% of iloperidone-treated patients with 
the optimal genotype combinations showed at least 20% improvement compared with just 37% 
for patients with other genotypes (62). 
Discussion 
First generation antipsychotics have facilitated hospital discharge and community psychiatric 
treatment, while SGA lead to lower risk of extrapyramidal and cognitive SE with better quality 
of life (63). On the other hand, SGAs have been associated with metabolic SE such as weight 
gain, lipid/glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis (63).  
Iloperidone was shown to be effective like haloperidol, risperidone and ziprasidone in reducing 
schizophrenia symptoms and preventing relapses (66). Common SE of iloperidone were mild 
including dizziness, hypotension, dry mouth and orthostatic hypotension (70). Similar to 
paliperidone, quetiapine and risperidone; iloperidone could cause weight gain and glucose 
imbalance especially in young, drug-naïve patients with healthy lifestyle counselling 
recommended (67). Iloperidone could also cause QTc prolongation, with low risk of akathisia, 
extrapyramidal symptoms compared to haloperidol and risperidone (68). This low risk may be 
linked to its alpha1 and HT2A antagonism (69). Patients using other antipsychotic (e.g. 
risperidone) can easily switch to iloperidone with no serious impact on safety or efficacy (2).  
Clinical judgment while taking scientific evidence and patients’ preferences in consideration is 
of primary importance in schizophrenia management (65). Although iloperidone clinical trials 
were conducted, effectiveness studies as well as safety data in elderly, young and pregnant 
patients are still lacking (71), especially elderly, who suffer from high comorbidity rates 
(psychiatric and medical); age-related pharmacokinetics changes and polypharmacy risk (72).  
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